Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals' stock price has experienced significant movement, with an 87.64% increase over the last year as of April 9, 2026. Key events impacting the stock price include the release of fourth quarter and full year 2025 financial results and business updates, the publication of clinical trial data, pipeline advancements, the appointment of Michael P. Miller to its Board of Directors, inducement grants, and a presentation at the J.P. Morgan Healthcare Conference. Strong earnings updates have occasionally seen negative follow-through, while positive clinical and management updates have generally aligned with modest gains.

While a comprehensive statement on demand seasonality for all of Rigel Pharmaceuticals' products and services is not explicitly detailed, there is an indication of external factors influencing demand for Tavalisse. The demand for Tavalisse surged in FY25, partly due to policy tailwinds, such as the elimination of the Medicare Part D coverage gap, which are expected to subside in FY26. This suggests that the demand for at least one of its major products can be influenced by changes in healthcare policy and may experience some level of seasonality or fluctuation based on such external factors.

Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and providing novel therapies, primarily for hematologic disorders and cancer. The company's research is centered on intracellular signaling pathways and related disease mechanisms. Rigel's major marketed products include Tavalisse for chronic immune thrombocytopenia, REZLIDHIA for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, and GAVRETO for RET+ metastatic NSCLC and RET+ advanced thyroid cancer. The company also has a pipeline of clinical programs, including R289 in a Phase 1b study for lower-risk myelodysplastic syndrome and a collaboration with Eli Lilly for Ocadusertib for immunological diseases.

Rigel Pharmaceuticals, Inc. is headquartered in South San Francisco, California. The company works with partners to bring its products to markets outside of the U.S., indicating an international reach through collaborations.

Rigel Pharmaceuticals' brand reputation in the past year appears to be generally positive, driven by strong financial performance, pipeline advancements, and positive analyst sentiment. The company's stock has seen a substantial increase, and analysts have a "Moderate Buy" consensus rating. Events that have positively affected Rigel's reputation include strong financial results, positive clinical data, and strategic partnerships. No specific events that have negatively affected Rigel Pharmaceuticals' reputation in the past year were prominently highlighted.

Rigel Pharmaceuticals, Inc. has significant institutional ownership, with 184 institutional owners holding a total of 15,435,824 shares as of April 8, 2026. Major institutional shareholders include BlackRock, Inc., The Vanguard Group, Inc., and State Street Corp. Bvf Partners L P is noted as the largest individual Rigel Pharmaceuticals shareholder, owning 16.66 million shares, representing 90.19% of the company.